Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer

Lévi, 1997, Chronopharmacology of anticancer agents, 299, 10.1007/978-3-662-09355-9_11 Smaaland, 1991, DNA synthesis in human bone marrow is circadian stage dependent, Blood, 77, 2603, 10.1182/blood.V77.12.2603.2603 Smaaland, 1992, DNA cell cycle distribution and glutathione (GSH) content according to circadian stage in bone marrow of cancer patients, Br J Cancer, 66, 39, 10.1038/bjc.1992.213 Harris, 1990, Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels: evidence for circadian variation of plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion, Cancer Res, 50, 197 Boughattas, 1989, Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane (trans-1) oxalatoplatinum (II) in mice, Cancer Res, 49, 3362 Metzger, 1994, Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in cancer patients, Clin PharmacolTher, 56, 190, 10.1038/clpt.1994.123 Cohen, 1993, Colon cancer, 929 Piedbois, 1992, Advanced colorectal cancer meta-analysis project: modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer—evidence in terms of response rate, J Clin Oncol, 10, 896, 10.1200/JCO.1992.10.6.896 Hryniuk, 1987, Applications of dose-intensity to problems in chemotherapy of breast and colorectal cancer, Semin Oncol, 14, 3 Poon, 1989, Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma, J Clin Oncol, 7, 1407, 10.1200/JCO.1989.7.10.1407 Scheithauer, 1993, Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer, BMJ, 306, 752, 10.1136/bmj.306.6880.752 Allen-Mersh, 1994, Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases, Lancet, 344, 1255, 10.1016/S0140-6736(94)90750-1 Lévi, 1993, Oxaliplatin activity against metastatic colorectal cancer: a phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate, Eur J Cancer, 29, 1280, 10.1016/0959-8049(93)90073-O Machover, 1996, Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines, Ann Oncol, 7, 95, 10.1093/oxfordjournals.annonc.a010489 Lévi, 1996, Chronotherapy for gastrointestinal cancers, Curr Opin Oncol, 8, 334, 10.1097/00001622-199607000-00012 Caussanel, 1990, Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate, J Natl Cancer Inst, 82, 1046, 10.1093/jnci/82.12.1046 Lévi, 1992, A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump: high antitumor effectiveness against metastatic colorectal cancer, Cancer, 69, 893, 10.1002/1097-0142(19920215)69:4<893::AID-CNCR2820690410>3.0.CO;2-X Lévi, 1994, Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with colorectal cancer metastases: a randomized multiinstitutional trial, J Natl Cancer Inst, 86, 1608, 10.1093/jnci/86.21.1608 O'Brien, 1979, A multiple testing procedure for clinical trials, Biometrics, 35, 549, 10.2307/2530245 Leichman, 1995, Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study, J Clin Oncol, 13, 1303, 10.1200/JCO.1995.13.6.1303 Hansen, 1996, Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer, J Natl Cancer Inst, 88, 668, 10.1093/jnci/88.10.668 Hill, 1995, Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival and quality of life in advanced colorectal cancer, J Clin Oncol, 13, 2317, 10.1200/JCO.1995.13.9.2317 Bertheault-Cvitkovic, 1996, Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with metastatic colorectal cancer, J Clin Oncol, 14(11), 2950, 10.1200/JCO.1996.14.11.2950 Lévi F, Dogliotti L, Perpoint B, et al. A multicentre phase II trial of intensified chronotherapy with oxaliplatin (L-OHP), 5-fluorouracil (5-FU) and folinic acid (FA) in patients (pts) with previously untreated metastatic colorectal cancer (MCC): Proceedings of 33rd Annual Meeting of American Society of Clinical Oncology, May 17–20, 1997. Denver, CO, USA; #945 (abstr). Glimelius, 1994, Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer, Cancer, 73, 556, 10.1002/1097-0142(19940201)73:3<556::AID-CNCR2820730310>3.0.CO;2-8 Buyse M, Molenberghs G, Criteria for the validation of surrogate end-points in randomized experiments. Biometrics (in press). Stangl, 1994, Factors influencing the natural history of colorectal liver metastases, Lancet, 343, 1405, 10.1016/S0140-6736(94)92529-1 Bismuth, 1996, Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy, Ann Surg, 224, 509, 10.1097/00000658-199610000-00009